ResearchMoz

Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies

GBI Research
Published Date » 2013-12-03
No. Of Pages » N/A
   
 GBI Research has released its pharma research, "Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies", which provides insights into two therapeutic indications in ophthalmology in Top Eight Markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications....
Table of Content

1 Table of Contents 1
1.1 List of Tables 4
1.2 List of Figures 4

2 Executive Summary 5
2.1 Ophthalmology Therapeutics in Major Markets is Expected to Reach $6.1 Billion by 2019, with Growth of 7.6% 5
2.2 Moderate Pipeline with Promising Drugs in Late Stages of Development could Drive Market Expectations 7

3 Ophthalmology Therapeutics in Major Markets – Introduction 9
3.1 Dry Eye Syndrome 9
3.1.1 Classification 9
3.1.2 Symptoms 9
3.1.3 Etiology 9
3.1.4 Pathophysiology 10
3.1.5 Diagnosis 11
3.1.6 Epidemiology 12
3.1.7 Prognosis 13
3.1.8 Treatment Options 13
3.2 Glaucoma 14
3.2.1 Classification 14
3.2.2 Symptoms 15
3.2.3 Etiology 15
3.2.4 Pathophysiology 16
3.2.5 Diagnosis 16
3.2.6 Epidemiology 17
3.2.7 Prognosis 18
3.2.8 Treatment Options 18
3.3 GBI Research Report Guidance 19

4 Ophthalmology Therapeutics in Major Markets – Marketed Products (Global) 19
4.1 Dry Eye Syndrome 19
4.2 Glaucoma 20
4.3 Key Marketed Products 21
4.3.1 Restasis 21
4.3.2 Systane 22
4.3.3 Diquas 23
4.3.4 Mucosta 24
4.3.5 Hyalein 25
4.3.6 Lumigan 26
4.3.7 Alphagan/Alphagan P 27
4.3.8 Simbrinza 28

5 Ophthalmology Therapeutics in Major Markets – Pipeline Analysis 28
5.1 Dry Eye Syndrome Pipeline 28
5.1.1 Overall Pipeline 28
5.1.2 Pipeline Analysis by Molecule Type 31
5.1.3 Pipeline Analysis by Mechanism of Action 33
5.2 Glaucoma Pipeline 35
5.2.1 Overall Pipeline 35
5.2.2 Pipeline Analysis by Molecule Type 37
5.2.3 Pipeline Analysis by Mechanism of Action 39
5.3 Promising Drug Candidates in the Pipeline 41
5.3.1 CF-101 41
5.3.2 MIM-D3 41
5.3.3 SAR-1118 41
5.3.4 DE-111 42

6 Ophthalmology Therapeutics in Major Markets – Market Forecast to 2019 42
6.1 Major Markets 42
6.1.1 Treatment Usage Patterns 42
6.1.2 Annual Cost of Therapy 42
6.1.3 Market Size 42
6.2 The US 44
6.2.1 Treatment Usage Patterns 44
6.2.2 Annual Cost of Therapy 44
6.2.3 Market Size 44
6.3 Top Five European Countries 46
6.3.1 Treatment Usage Patterns 46
6.3.2 Annual Cost of Therapy 46
6.3.3 Market Size 46
6.4 Canada 48
6.4.1 Treatment Usage Patterns 48
6.4.2 Annual Cost of Therapy 48
6.4.3 Market Size 48
6.5 Japan 50
6.5.1 Treatment Usage Patterns 50
6.5.2 Annual Cost of Therapy 50
6.5.3 Market Size 50
6.6 Drivers and Barriers 52
6.6.1 Drivers 52
6.6.2 Barriers 52

7 Ophthalmology Therapeutics in Major Markets – Deals and Strategic Consolidations (Global) 53
7.1 Deals Analysis 53
7.2 Major Co-Development Deals 55
7.2.1 NicOx Signs Research Agreement with Pfizer 56
7.2.2 Acucela Enters into Co-development Agreement with Otsuka Pharma for Rebamipide 56
7.2.3 Akorn Enters into Agreement with Azad Pharma 56
7.3 Major Licensing Deals 57
7.3.1 NicOx Enters into Worldwide Licensing Agreement with Bausch & Lomb 58
7.3.2 Quark Pharma Amends Licensing Agreement with Pfizer for PF-655 58
7.3.3 Asterand Enters into Licensing Agreement with Allergan 58

8 Ophthalmology Therapeutics in Major Markets – Appendix 58
8.1 All Pipeline Drugs by Phase 58
8.1.1 Discovery 58
8.1.2 Preclinical 59
8.1.3 IND/CTA-filed 60
8.1.4 Phase I 60
8.1.5 Phase II 62
8.1.6 Phase III 63
8.1.7 Pre-registration 63
8.1.8 Undisclosed 64
8.2 Market Forecasts to 2019 64
8.2.1 Major Markets 64
8.2.2 The US 65
8.2.3 The UK 65
8.2.4 France 66
8.2.5 Germany 67
8.2.6 Italy 67
8.2.7 Spain 68
8.2.8 Canada 69
8.2.9 Japan 69
8.3 Market Definitions 70
8.4 Abbreviations 70
8.5 Sources 72
8.6 Research Methodology 73
8.6.1 Coverage 74
8.6.2 Secondary Research 74
8.6.3 Primary Research 74
8.6.4 Therapeutic Landscape 75
8.6.5 Geographical Landscape 78
8.6.6 Pipeline Analysis 78
8.7 Expert Panel Validation 78
8.8 Contact Us 78
8.9 Disclaimer 78

List of Tables


Table 1: Ophthalmology Therapeutics Market, Categories of Dry Eye Treatment, 2011 13
Table 2: Ophthalmology Therapeutics Market, Treatment Recommendations for Dry Eye Syndrome by Disease Severity Level, 2011 14
Table 3: Ophthalmology Therapeutics Market, Medicines for Lowering Eye Pressure, 2013 18
Table 4: Ophthalmology Therapeutics Market, Global, Pipeline (Discovery), 2013 58
Table 5: Ophthalmology Therapeutics Market, Global, Pipeline (Preclinical), 2013 59
Table 6: Ophthalmology Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 60
Table 7: Ophthalmology Therapeutics Market, Global, Pipeline (Phase I), 2013 60
Table 8: Ophthalmology Therapeutics Market, Global, Pipeline (Phase II), 2013 62
Table 9: Ophthalmology Therapeutics Market, Global, Pipeline (Phase III), 2013 63
Table 10: Ophthalmology Therapeutics Market, Global, Pipeline (Pre-registration), 2013 63
Table 11: Ophthalmology Therapeutics Market, Global, Pipeline (Undisclosed), 2012 64
Table 12: Ophthalmology Therapeutics Market, Major Markets,, Dry Eye Syndrome, Market Forecast, 2012–2019 64
Table 13: Ophthalmology Therapeutics Market, Major Markets, Glaucoma, Market Forecast, 2012–2019 64
Table 14: Ophthalmology Therapeutics Market, The US, Dry Eye Syndrome, Market Forecast, 2012–2019 65
Table 15: Ophthalmology Therapeutics Market, The US, Glaucoma, Market Forecast, 2012–2019 65
Table 16: Ophthalmology Therapeutics Market, The UK, Dry Eye Syndrome, Market Forecast, 2012–2019 65
Table 17: Ophthalmology Therapeutics Market, The UK, Glaucoma, Market Forecast, 2012–2019 66
Table 18: Ophthalmology Therapeutics Market, France, Dry Eye Syndrome, Market Forecast, 2012–2019 66
Table 19: Ophthalmology Therapeutics Market, France, Glaucoma, Market Forecast, 2012–2019 66
Table 20: Ophthalmology Therapeutics Market, Germany, Dry Eye Syndrome, Market Forecast, 2012–2019 67
Table 21: Ophthalmology Therapeutics Market, Germany, Glaucoma, Market Forecast, 2012–2019 67
Table 22: Ophthalmology Therapeutics Market, Italy, Dry Eye Syndrome, Market Forecast, 2012–2019 67
Table 23: Ophthalmology Therapeutics Market, Italy, Glaucoma, Market Forecast, 2012–2019 68
Table 24: Ophthalmology Therapeutics Market, Spain, Dry Eye Syndrome, Market Forecast, 2012–2019 68
Table 25: Ophthalmology Therapeutics Market, Spain, Glaucoma, Market Forecast, 2012–2019 68
Table 26: Ophthalmology Therapeutics Market, Canada, Dry Eye Syndrome, Market Forecast, 2012–2019 69
Table 27: Ophthalmology Therapeutics Market, Canada, Glaucoma, Market Forecast, 2012–2019 69
Table 28: Ophthalmology Therapeutics Market, Japan, Dry Eye Syndrome, Market Forecast, 2012–2019 69
Table 29: Ophthalmology Therapeutics Market, Japan, Glaucoma, Market Forecast, 2012–2019 70

List of Figures


Figure 1: Ophthalmology Therapeutics Market, Major Markets, Market Size (bn), 2012–2019 6
Figure 2: Ophthalmology Therapeutics Market, Global, Pipeline by Stage (%), 2013 8
Figure 3: Ophthalmology Therapeutics Market, Global, Sales of Restasis ($m), 2006–2012 21
Figure 4: Ophthalmology Therapeutics Market, Global, Sales of Diquas ($m), 2010–2012 23
Figure 5: Ophthalmology Therapeutics Market, Global, Sales of Mucosta ($m), 2009–2012 24
Figure 6: Ophthalmology Therapeutics Market, Global, Sales of Hyalein ($m), 2009–2012 25
Figure 7: Ophthalmology Therapeutics Market, Global, Sales of Lumigan ($m), 2006–2012 26
Figure 8: Ophthalmology Therapeutics Market, Global, Sales of Alphagan/Alphagan P ($m), 2006–2012 27
Figure 9: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline (%), 2013 29
Figure 10: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Molecule Type, 2013 32
Figure 11: Ophthalmology Therapeutics Market, Global, Dry Eye Syndrome, Pipeline by Mechanism of Action, 2012 34
Figure 12: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline, 2013 36
Figure 13: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Molecule Type, 2013 38
Figure 14: Ophthalmology Therapeutics Market, Global, Glaucoma, Pipeline by Mechanism of Action, 2013 40
Figure 15: Ophthalmology Therapeutics Market, Major Markets, Market Size, 2012–2019 43
Figure 16: Ophthalmology Therapeutics Market, The US, Market Size, 2012–2019 45
Figure 17: Ophthalmology Therapeutics Market, Top Five European Countries, Market Size, 2012–2019 47
Figure 18: Ophthalmology Therapeutics Market, Canada, Market Size ($m), 2012–2019 49
Figure 19: Ophthalmology Therapeutics Market, Japan, Market Size ($m), 2012–2019 51
Figure 20: Ophthalmology Therapeutics Market, Global, Deals, 2006–2013 54
Figure 21: Ophthalmology Therapeutics Market, Global, Co-Development Deals, 2006–2013 55
Figure 22: Ophthalmology Therapeutics Market, Global, Licensing Deals, 2006–2013 57
Figure 23: GBI Research Market Forecasting Model 77

Upcoming Reports:

Fuel Cell Vehicles Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Fuel cell technology is unique and has the potential to power forklifts, airport tugs, passenger vehicles and heavy duty vehicles. Major automobile companies have started fuel cell vehicle programs, and the technology has rapidly advanced thereby gaining popularity, over the last few years. Fuel cell vehicles have made considerable progress towards meeting the goals set by the U.S. Department of Energy. Some first generation fuel cell vehicles have shown immaculate durability, which indicates significant progress toward meeting the goals set by the authorities. Present generation...
Computerized Physician Order Entry (CPOE) Systems Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Computerized physician order entry (CPOE) system is a form of software system that allows the direct entry of medical prescription orders and other instructions for the treatment of patients by a doctor. These orders by physicians are filled by other medical staff such as pharmacists, radiologists, nurses and pathologists who are communicated through computer network. This system is a substitute to paper-based ordering system.A CPOE system offersnumerous advantages over paper-based ordering system; some majors are as follows: Reduces delay in order completion Reduces errors...
Poland: sunflower oil market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the sunflower oil market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the sunflower oil market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Low Gas Prices Hurt Utahs Energy Industry
Dec 18, 2014  
Due to excessive petroleum on the global market, gas prices are heavily tumbling in several places of the world. This aspect could prove effective and great for consumers in most parts of the world, but it is not so for the Utah. The petroleum industry in Utah has a tough time with the state budget.  In Utah, the average gas prices have declined to around $2.64 a gallon. This has...
The 3 Dining Trend to Look Out For in 2015
Dec 17, 2014  
Dining is a vibrant, dynamic subject. You can never set down a list of definitive rules for it, and since it depends on our own fickle taste, it is always subject to drastic changes and welcoming to new trends. Here’s a list of dining trends that are on the cusp of becoming mainstream and will surely make that step up in the coming year. 1. Increasing Acceptance of Technology:...
Bolivian Air Force Receives the Super Puma Helicopters
Dec 16, 2014  
It was declared by the Airbus Helicopters that the Bolivian Air Force was the recipient of second of the six Airbus AS332 C1e Super Puma helicopters. The Super Pumas are generally used for several internal security missions and counter narcotics. The rest of the four helicopters will start operating from the year 2016. In late 2013, the light medium helicopters were purchased by the FAB for...
Leaked Emails Prove to be Challenging for Sony
Dec 15, 2014  
It has been revealed via leaked emails that there exists a cultural gulf between Sony Pictures Entertainment, the Hollywood subsidiary on the one hand and Japan’s Sony Corp on the other. This poses a major challenge to the CEO Kazuo Hirai to bring about positive changes in the loss making company under the One Sony slogan.  Over the past six years, this has been the fifth...
British Construction Firms to Hire More by 2015
Dec 10, 2014  
As per the latest survey carried out by Manpower, increasing workload in Britain’s construction industry is calling for rise in employment opportunities. It is expected that in the coming year, various construction firms will be on a hiring spree. Paucity of trained and skilled workers in U.K. based building firms has led to greater focus on hiring of Portuguese bricklayers at a wage...